NSE மற்றும் BSE-யின் ஒவ்வொரு கார்ப்பரேட் அறிவிப்பும், AI-யால் சில நிமிடங்களில் படிக்கப்பட்டு விளக்கப்படுகிறது — தாக்கம், முக்கிய புள்ளிவிவரங்கள், குறுகிய/நீண்டகாலப் பார்வை, கவனிக்க வேண்டியவை.
நேரலைசமீபத்திய அறிவிப்பு: 6 மணி நேரத்திற்கு முன்இன்று 0 பகுப்பாய்வு செய்யப்பட்டது
குறிப்பு: இவை NSE பொது அறிக்கைகளின் AI-உருவாக்கிய, கல்வி நோக்கச் சுருக்கங்கள் — ஒவ்வொரு ஆவணத்தையும் ஆதாரமாகக் கொண்டவை, ஆனால் முதலீட்டு ஆலோசனை அல்ல, மேலும் முழுமையற்றதாகவும் இருக்கலாம். அசல் அறிக்கையுடன் சரிபார்க்கவும், செயல்படுவதற்கு முன் SEBI-பதிவு பெற்ற முதலீட்டு ஆலோசகரை அணுகவும்.
Kilitch Issues EGM Corrigendum on $12.855M Subsidiary Stake Sale to HarmeeCare
Kilitch Drugs (India) Limited issued a corrigendum to its EGM notice for the meeting scheduled on November 16, 2026. The company corrected a typographical error regarding the debt-to-equity conversion in subsidiary Kilitch Estro Biotech PLC (KEB), stating it will receive 1,66,471 shares (instead of 1,66,472 shares). Upon conversion, Kilitch's stake in KEB increases from 67% to 89.17% before being fully sold to HarmeeCare Pharmaceuticals. The cumulative sale consideration for KEB remains unchanged at USD 12.855 million (~Rs 108 Cr, or ~45% of TTM revenue).
உச்சம் நம்பிக்கை
என்ன மாறியதுCorrected a 1-share typographical error in the EGM notice explanatory statement regarding the number of KEB shares allotted upon debt conversion (1,66,471 vs 1,66,472).
ஏன் இது முக்கியம்Clarifies legal terms for the USD 12.855 million divestment of its KEB subsidiary, a substantial transaction worth nearly a quarter of Kilitch's Rs 467 Cr market cap.
Total sale consideration: USD 12,855,000Shares to be allotted via conversion: 1,66,471KEB post-conversion holding: 89.17%KEB pre-conversion holding: 67%EGM date: 16th நவம்பர், 2026
📅 குறுகிய காலம்Shareholders will vote on the KEB disposal and debt conversion at the November 16, 2026 EGM; approval is expected given 63.8% promoter control.
📈 நீண்ட காலம்The divestment unlocks substantial liquidity of USD ~12.855M to pay down Rs 96 Cr of existing debt or redeploy toward domestic and international injectable capacity expansions.
⚠ அபாய எச்சரிக்கைகள்
Completion of the KEB transaction remains contingent on shareholder and regulatory clearances
Loss of revenue contribution from subsidiary Kilitch Estro Biotech PLC post-sale
👀 கவனிக்க வேண்டியவை
Track the outcome of shareholder voting at the EGM on November 16, 2026, and monitor regulatory approvals alongside the timeline for cash inflow of USD 12.855 million.
Kilitch Drugs Q2 PAT Falls 53% YoY; Approves Divestment of Ethiopian Subsidiary for $14M
Kilitch Drugs reported Q2 standalone net sales of Rs 43.49 crore, up 15% YoY from Rs 37.81 crore, while net profit dropped 52.9% YoY to Rs 4.10 crore due to higher finance costs and depreciation. For H1, net profit stood at Rs 9.15 crore compared to Rs 13.51 crore in the prior period. Concurrently, the Board approved converting Rs 57.00 crore of debt into equity in its Ethiopian subsidiary, Kilitch Estro Biotech PLC (KEB), and divesting the entire stake to HarmeeCare Pharmaceuticals for USD 14.00 million, with USD 12.855 million payable to Kilitch.
உச்சம் நம்பிக்கை
என்ன மாறியதுKilitch Drugs reported Q2 financial results and formally approved the complete divestment of loss-making subsidiary Kilitch Estro Biotech PLC for USD 14 million.
ஏன் இது முக்கியம்The divestment of the Ethiopian unit will bring in USD 12.855 million (nearly a quarter of current market cap of Rs 455 Cr) and remove a drag of recurring operating losses (KEB lost Rs 5.33 Cr in H1).
Q2 Net Sales: Rs 4,349.26 LakhsQ2 PAT: Rs 410.19 LakhsDebt Conversion Amount: Rs 57.00 croreTotal Divestment Consideration: USD 14.00 millionConsideration Payable to Company: USD 12.855 million
📅 குறுகிய காலம்Earnings show operational margin compression from sharp increases in finance and depreciation costs, but the USD 12.855M cash inflow announcement from the divestment may support sentiment.
📈 நீண்ட காலம்Exiting the volatile Ethiopian subsidiary eliminates ongoing currency risks and operating losses, while the capital inflow can substantially strengthen the balance sheet or fund domestic expansions.
⚠ அபாய எச்சரிக்கைகள்
Regulatory and FEMA approval risks for cross-border divestment and overseas debt-to-equity conversion
Significant YoY profit compression on standalone operations
👀 கவனிக்க வேண்டியவை
Track statutory and FEMA regulatory approvals for the $12.855M Ethiopian subsidiary divestment, as well as timeline and realization of cash proceeds.
Kilitch to Divest Ethiopia Subsidiary for $14M Total, Company Share $12.855M; Calls Nov 16 EGM
Kilitch Drugs has issued an Extraordinary General Meeting (EGM) notice for November 16, 2026, seeking shareholder approval to sell its entire stake in its material Ethiopian subsidiary, Kilitch Estro Biotech PLC. The subsidiary is being sold to HarmeeCare Pharmaceuticals, an Ethiopian state-owned enterprise, for a total consideration of USD 14,000,000 (~Rs 117 Cr+), with Kilitch Drugs set to receive USD 12,855,000 (~Rs 108 Cr). This expected inflow represents ~45% of the company's TTM revenue (Rs 237 Cr) and ~23% of its market cap (Rs 471 Cr). Shareholders will also vote on converting existing debt extended to the subsidiary into equity prior to the sale completion.
உச்சம் நம்பிக்கை
என்ன மாறியதுKilitch Drugs has agreed to fully exit its Ethiopian subsidiary Kilitch Estro Biotech PLC by selling it to state-owned HarmeeCare Pharmaceuticals.
ஏன் இது முக்கியம்The sale unlocks USD 12.855M (~Rs 108 Cr) in cash, significantly boosting liquidity and eliminating foreign exchange exposure and geopolitical risks tied to Ethiopia.
Total Deal Consideration: USD 14,000,000Consideration Due to Company: USD 12,855,000Company Proceeds vs TTM Revenue (~Rs 108 Cr / Rs 237 Cr): ~45.6%EGM Date: நவம்பர் 16, 2026Voting Cut-Off Date: நவம்பர் 6, 2026
📅 குறுகிய காலம்Market reaction is likely to be positive given the sizeable cash inflow relative to market cap (~23%) and the de-risking of foreign asset operations.
📈 நீண்ட காலம்Exiting Ethiopia streamlines operations, allows management to reallocate capital into domestic high-margin parenteral manufacturing, and eliminates forex volatility from the region.
⚠ அபாய எச்சரிக்கைகள்
Regulatory approvals required from SEBI, RBI, FEMA overseas investment guidelines, and Ethiopian regulators
Requires majority approval from public shareholders under SEBI Regulation 37A
Potential foreign exchange or repatriation delays from Ethiopia
👀 கவனிக்க வேண்டியவை
Track the outcome of the November 16, 2026 EGM and the required majority-of-minority approval under Regulation 37A. Watch for details on cross-border remittance approvals under FEMA and the deployment plan for the USD 12.855M proceeds.
Kilitch Drugs to Divest Entire Stake in Ethiopian Unit for $14 Million
Kilitch Drugs (India) Limited has announced the proposed divestment of its entire stake in its Ethiopian subsidiary, Kilitch Estro Biotech PLC (KEB), to Ethiopian state-owned HarmeeCare Pharmaceuticals for US$14 million (~Rs 117 Cr, ~25% of market cap). The company plans to deploy net proceeds to reduce existing debt (total debt currently at Rs 88 Cr) and fund the phased expansion of its Pen, Maharashtra facility for parenterals and GLP-1 therapies. In addition, Kilitch intends to retain a commercial presence in Ethiopia through a long-term supply and technical services agreement. The transaction is slated for completion by January 31, 2027, subject to shareholder and regulatory approvals.
உச்சம் நம்பிக்கை
என்ன மாறியதுKilitch Drugs agreed to sell 100% of its Ethiopian subsidiary to a state-owned enterprise for US$14 million, pivoting away from direct overseas manufacturing.
ஏன் இது முக்கியம்The proceeds (worth ~25% of market cap and ~49% of TTM revenue) will significantly deleverage the balance sheet (debt of Rs 88 Cr) and reallocate capital into higher-margin Indian manufacturing including GLP-1 injectables.
Transaction Value: US$14 millionDeal Value vs Market Cap: ~25%Deal Value vs TTM Revenue: ~49%Current Total Debt: Rs 88 கோடிExpected Completion Date: ஜனவரி 31, 2027
📅 குறுகிய காலம்Positive sentiment likely driven by significant balance sheet deleveraging potential and cash inflow, though closing depends on approvals.
📈 நீண்ட காலம்Exiting Ethiopian operations removes African forex/operating volatility while capitalising expansion at the Pen facility into regulated markets and GLP-1 therapies.
⚠ அபாய எச்சரிக்கைகள்
Subject to shareholder approval and regulatory clearances
Extended timeline with completion slated by January 31, 2027
Execution risk on obtaining EU GMP / PIC/S accreditations for the Pen facility
👀 கவனிக்க வேண்டியவை
Track the shareholder voting timeline and subsequent closing conditions ahead of the January 31, 2027 completion target, alongside updates on debt reduction and execution at the Pen facility.
Kilitch Drugs to Divest Ethiopian Unit for USD 12.855M After INR 57 Cr Debt Conversion
Kilitch Drugs has approved the sale of its entire shareholding in Ethiopian subsidiary Kilitch Estro Biotech PLC (KEB) to HarmeeCare Pharmaceuticals, an Ethiopian state-owned enterprise, for a total deal value of USD 14.0M, with USD 12.855M (~INR 107 Cr at typical exchange rates) due to Kilitch. Prior to the sale, Kilitch will convert its outstanding debt and service costs of up to INR 57.00 Cr in KEB into 1,66,472 equity shares at Rs 3,414 per share to comply with FEMA regulations. KEB accounted for INR 47.57 Cr (20.20%) of consolidated FY26 turnover and had a negative net worth of INR (8.43) Cr as of March 31, 2026. The transaction is targeted for completion by January 31, 2027, subject to shareholder approval under Regulation 37A.
உச்சம் நம்பிக்கை
என்ன மாறியதுKilitch Drugs agreed to convert INR 57 Cr in loans into equity and fully exit its Ethiopian manufacturing subsidiary KEB by selling to a state-owned enterprise.
ஏன் இது முக்கியம்The company monetizes a net-worth-negative foreign subsidiary, recovering substantial capital (~USD 12.855M) relative to its market cap of Rs 471 Cr and resolving foreign exchange exposure.
Consideration due to company: USD 12,855,000Debt converted to equity: INR 57.00 CroresKEB FY26 revenue: INR 47.57 CroresKEB revenue share of consolidated FY26: 20.20%KEB Net Worth as of 31-Mar-2026: INR (8.43) Crores
📅 குறுகிய காலம்Positive sentiment likely due to cash realization and exit from a loss-making/negative net-worth overseas operation.
📈 நீண்ட காலம்Reduces consolidated revenue by ~20% but eliminates overseas operational and forex volatility, strengthening the balance sheet if proceeds are used to pare debt or redeploy into domestic formulations.
⚠ அபாய எச்சரிக்கைகள்
Cross-border transaction completion risk and regulatory compliance under FEMA
Definitive Share Purchase Agreement is pending final signing following binding minutes
👀 கவனிக்க வேண்டியவை
Track shareholder approval at the upcoming EGM and the execution of the formal Share Purchase Agreement ahead of the January 31, 2027 completion target.
📊 கடந்த 7 நாட்கள் — உணர்வு அடிப்படையில் பகுப்பாய்வு செய்யப்பட்ட அறிவிப்புகள்
4% YoY Revenue Growth in Q1 FY27; Consolidated PAT Declines 13% to Rs 1.97 Cr
Kilitch Drugs reported a modest 4% YoY increase in consolidated revenue to Rs 44.88 Cr for Q1 FY27. However, consolidated net profit declined by 13% YoY to Rs 1.97 Cr, primarily dragged down by losses in its foreign subsidiary, Kilitch Estro Biotech PLC, which reported a loss of Rs 2.87 Cr. Standalone operations remained robust with a PAT of Rs 5.05 Cr, suggesting the core Indian business is subsidizing international expansion losses. Total comprehensive income was supported by a significant Rs 5.00 Cr gain in other comprehensive income, likely due to currency fluctuations or asset revaluation.
உச்சம் நம்பிக்கை
என்ன மாறியதுThe company reported its first-quarter results for FY27, showing steady standalone performance but increased drag from international subsidiaries.
ஏன் இது முக்கியம்The results highlight the execution risk of the company's international expansion strategy; while standalone Indian operations are profitable, the consolidated bottom line is sensitive to the performance of foreign units and exchange rate volatility.
Consolidated Revenue (Q1): Rs 44.88 கோடிConsolidated PAT (Q1): Rs 1.97 கோடிRevenue vs TTM Revenue: 19.1%Foreign Subsidiary Loss: Rs 2.87 கோடிStandalone PAT: Rs 5.05 கோடி
📅 குறுகிய காலம்The stock may face mild pressure due to the YoY decline in consolidated PAT and the significant sequential drop in revenue compared to Q4 FY26.
📈 நீண்ட காலம்The long-term outlook depends on the company's ability to scale its high-margin parenteral range and turn its international subsidiaries profitable.
⚠ அபாய எச்சரிக்கைகள்
Loss-making foreign subsidiaries
High sequential revenue volatility
Significant impact of Other Comprehensive Income on total earnings
👀 கவனிக்க வேண்டியவை
Monitor the path to profitability for the foreign subsidiary Kilitch Estro Biotech PLC, as its current losses are significantly eroding standalone profits. Watch for stabilization in quarterly revenue, which saw a sharp 50% sequential decline from the outlier Q4 FY26 performance.
Kilitch Drugs Commences Nutraceutical Manufacturing at New Raigad Plant
Kilitch Drugs (India) Limited has officially commenced operations at its new Nutraceutical Manufacturing Block located in Raigad, Maharashtra. The facility, situated at Village Maldev, Taluka Pen, began commercial production on June 17, 2026. This expansion marks a strategic move into the nutraceutical segment, which is expected to diversify the company's revenue streams beyond traditional pharmaceuticals. The commencement follows the company's regulatory compliance under SEBI Listing Obligations.
முக்கிய அம்சங்கள்
Commencement of operations at the new Nutraceutical Manufacturing Block on June 17, 2026.Facility located at 24/2/1/1, Village: Maldev, Taluka: Pen, District: Raigad, Maharashtra.Strategic expansion into the high-growth nutraceutical sector to enhance product portfolio.Compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
👀 கவனிக்க வேண்டியவை
Investors should monitor the incremental revenue contribution from this new nutraceutical block in the upcoming quarterly results. The expansion suggests a positive outlook for capacity growth and market diversification.
Kilitch Drugs Reports 23% PAT Growth in Q4 FY26; FY26 Revenue at ₹188.6 Crore
Kilitch Drugs (India) Limited reported a strong Q4 FY26 with net sales growing 27.8% year-on-year to ₹71.97 crore. Net profit for the quarter rose 23.1% to ₹14.00 crore compared to ₹11.37 crore in the previous year's corresponding quarter. On a full-year basis, the company maintained steady performance with total income reaching ₹202.42 crore and PAT at ₹32.40 crore. Notably, the company completed a 1:1 bonus issue in March 2026, which has adjusted the earnings per share figures for the period.
முக்கிய அம்சங்கள்
Q4 FY26 Net Sales increased by 27.8% YoY to ₹7,196.88 Lakhs.Quarterly Net Profit (PAT) grew 23.1% YoY to ₹1,399.90 Lakhs.Full-year FY26 Total Income stood at ₹20,242.28 Lakhs, a 3.6% increase over FY25.Successfully executed a 1:1 bonus issue with allotment of 1,74,80,782 shares on March 25, 2026.Export Product Registration and Commission expenses stood at ₹24.39 crore for the full year.
👀 கவனிக்க வேண்டியவை
Investors should monitor the company's export-driven growth momentum which significantly boosted Q4 results. The 1:1 bonus issue has improved liquidity, but investors should evaluate the stock based on its steady 4% annual PAT growth.
Kilitch Drugs Allots 1.75 Crore Bonus Shares in 1:1 Ratio
Kilitch Drugs (India) Limited has officially approved the allotment of 1,74,80,782 bonus equity shares to its shareholders. The allotment is based on a 1:1 ratio, meaning shareholders receive one new share for every one share held as of the record date, March 24, 2026. This corporate action has resulted in the doubling of the company's paid-up equity share capital from Rs. 17.48 crore to Rs. 34.96 crore. The new shares will rank pari-passu with existing shares, effectively increasing the stock's liquidity in the market.
முக்கிய அம்சங்கள்
Allotment of 1,74,80,782 bonus equity shares with a face value of Rs. 10 each.Bonus issue ratio maintained at 1:1 for all eligible shareholders as of March 24, 2026.Total paid-up share capital increased from Rs. 17,48,07,820 to Rs. 34,96,15,640.Total number of equity shares post-allotment stands at 3,49,61,564.The board meeting concluded on March 25, 2026, finalizing the issuance process.
👀 கவனிக்க வேண்டியவை
Investors should account for the increased share count in their portfolios and the proportional adjustment in the market price. The bonus issue is a positive signal of management's confidence and aims to improve retail participation through better liquidity.
Kilitch Drugs Sets March 24, 2026 as Record Date for 1:1 Bonus Issue
Kilitch Drugs (India) Limited has officially announced March 24, 2026, as the record date for its 1:1 bonus share issue. Shareholders holding the company's equity shares of face value Rs. 10 each as of the record date will be eligible to receive one additional share for every share held. The deemed date for the allotment of these bonus shares is set for March 25, 2026. This move follows the necessary shareholder approvals and aims to increase the liquidity of the stock in the market.
முக்கிய அம்சங்கள்
Bonus issue ratio of 1:1 (one new share for every one existing share held)Record date for determining eligibility is Tuesday, March 24, 2026Deemed date of allotment for bonus shares is Wednesday, March 25, 2026Face value of the equity shares remains at Rs. 10 per share
👀 கவனிக்க வேண்டியவை
Existing shareholders should hold their positions through the record date to receive the bonus shares. New investors should be aware that the stock price will adjust downwards proportionally on the ex-bonus date.
Kilitch Drugs Approves 1:1 Bonus Issue and Increase in Authorized Capital at EGM
Kilitch Drugs (India) Limited successfully conducted its Extraordinary General Meeting (EGM) on March 13, 2026. Shareholders approved the issuance of bonus shares in a 1:1 ratio, meaning investors will receive one additional share for every share held. The meeting also authorized an increase in the company's share capital and necessary amendments to the Memorandum of Association. The record date for the bonus allotment will be determined and announced by the Board in due course.
முக்கிய அம்சங்கள்
Approval of 1:1 Bonus Issue for all eligible shareholders as of the upcoming record dateResolution passed to increase the Authorized Capital of the company and amend the Memorandum of AssociationEGM held on March 13, 2026, with participation from 3 promoter group members and 45 public shareholdersThe meeting was conducted via video conferencing and concluded within 12 minutes with all resolutions transacted
👀 கவனிக்க வேண்டியவை
Existing shareholders should monitor for the announcement of the record date to ensure eligibility for the 1:1 bonus shares. Note that while share count will double, the stock price will adjust proportionally on the ex-bonus date.
Kilitch Drugs Announces 1:1 Bonus Issue and Increase in Authorized Capital
Kilitch Drugs (India) Limited has scheduled an Extraordinary General Meeting (EGM) on March 13, 2026, to seek shareholder approval for a 1:1 bonus share issuance. The company plans to capitalize up to INR 17.48 crore from its Free Reserves or Securities Premium to issue approximately 1.75 crore new equity shares. To facilitate this, the authorized share capital will be increased from INR 25 crore to INR 40 crore. Shareholders on record as of March 4, 2026, will be eligible for e-voting on these proposals.
முக்கிய அம்சங்கள்
Proposed 1:1 bonus issue, providing one new equity share for every one existing share heldIncrease in Authorized Share Capital from INR 25,00,00,000 to INR 40,00,00,000Capitalization of a sum not exceeding INR 17,48,07,820 from reserves for the bonus issueEGM to be held on March 13, 2026, with remote e-voting from March 9 to March 12, 2026Cut-off date for determining e-voting eligibility is March 4, 2026
👀 கவனிக்க வேண்டியவை
Investors should monitor the official announcement of the Record Date following the EGM approval to ensure eligibility for the bonus shares. While the number of shares will double, the stock price will adjust proportionally, improving liquidity for retail participants.
Kilitch Drugs (India) Limited has recommended a 1:1 bonus issue, providing one free equity share for every share held, subject to shareholder approval. For Q3 FY26, the company reported a massive 170% year-on-year surge in standalone revenue to ₹44.67 crore, although net profit declined to ₹4.89 crore from ₹6.88 crore in the same period last year. The company is also increasing its authorized share capital to ₹40 crore to facilitate the bonus issuance. These developments follow a recent ₹49.92 crore rights issue aimed at funding a Greenfield Project at Pen, signaling aggressive expansion.
முக்கிய அம்சங்கள்
Approved 1:1 Bonus Issue by capitalizing free reserves and securities premium of ₹17.48 crore.Standalone Q3 FY26 revenue from operations rose to ₹44.67 crore versus ₹16.51 crore in Q3 FY25.Net profit for the quarter stood at ₹4.89 crore, impacted by higher material costs and export commissions.Authorized share capital increased from ₹25 crore to ₹40 crore to accommodate the new equity base.Recently completed a ₹49.92 crore rights issue in August 2025 for capital expenditure on a Greenfield Project.
👀 கவனிக்க வேண்டியவை
The 1:1 bonus issue is a positive signal for retail liquidity, though investors should monitor the compression in net profit margins despite the high revenue growth. The progress of the Greenfield Project at Pen will be the primary driver for long-term value creation.
Kilitch Drugs (India) Limited has approved a 1:1 bonus issue, meaning shareholders will receive one additional share for every share held as of the record date. The company reported a significant jump in standalone revenue for Q3 FY26 to ₹4,467 lakhs, up from ₹1,651 lakhs in the same quarter last year. However, standalone net profit for the quarter declined to ₹489 lakhs from ₹688 lakhs YoY due to increased operational expenses. The board has also proposed increasing the authorized share capital from ₹25 crore to ₹40 crore to facilitate the bonus issuance.
முக்கிய அம்சங்கள்
Approved 1:1 bonus issue by capitalizing ₹17.48 crore from free reserves and securities premium.Standalone Q3 FY26 revenue grew 170% YoY to ₹4,467 lakhs from ₹1,651 lakhs.Standalone Net Profit for Q3 FY26 stood at ₹489.08 lakhs compared to ₹688.30 lakhs YoY.Authorized share capital increased to ₹40 crore from ₹25 crore, subject to shareholder approval.Bonus shares are expected to be credited or dispatched by April 10, 2026.
👀 கவனிக்க வேண்டியவை
Investors should maintain a positive outlook due to the bonus issue which will enhance liquidity, though the dip in net profit despite high revenue growth warrants a closer look at margin pressures. Monitor the EGM on March 13, 2026, for final approval and the subsequent announcement of the record date.
⚠️இந்தத் தளம் எவ்வாறு உருவாக்கப்படுகிறது: சந்தைத் தரவுப் பக்கங்கள் NSE/BSE வெளியீடுகள் மற்றும் நிறுவனங்களின் தாக்கல்களிலிருந்து தானாகக் கணக்கிடப்படுகின்றன; செய்திக் கட்டுரைகளும் அறிவிப்புப் பகுப்பாய்வுகளும் AI உதவியுடன் எழுதப்படுகின்றன, மனித மேற்பார்வையுடன்: AI உருவாக்குவதை எங்கள் ஆசிரியர்கள் மதிப்பாய்வு செய்கின்றனர். இரண்டிலும் பிழைகள் இருக்கலாம். எந்தவொரு முதலீட்டு முடிவுக்கு முன்பும் அசல் மூலங்களில் சரிபார்க்கவும். முதலீட்டு ஆலோசனை அல்ல; Flash Finance SEBI-பதிவு பெற்றது அல்ல. நாங்கள் AI-ஐ எவ்வாறு பயன்படுத்துகிறோம்
🎁 ஆரம்பகால ஆதரவாளர்களுக்கு மட்டும் · குறுகிய கால சலுகை
எங்கள் AI பங்குச் சந்தை பகுப்பாய்வு: டெலிகிராம், வாட்ஸ்அப்பில் இலவசம்
⚡ 3500+ நிறுவனங்களை நாங்கள் உடனுக்குடன் கண்காணிக்கிறோம். NSE-யில் ஒரு நிறுவன அறிவிப்பு வெளியானதுமே, எங்கள் AI அதைப் படித்து, சுருக்கி, அதன் தாக்கத்தைச் சில நொடிகளில் உங்களுக்குச் சொல்கிறது.
இதுபோன்ற AI பகுப்பாய்வுக்குக் கட்டணத் தளங்கள் ஆண்டுக்கு ₹1,00,000-க்கும் மேல் வசூலிக்கின்றன. எங்கள் சேனல்களில் இது இலவசம்.
